A Multicenter Retrospective Analysis Stressing Importance of Tracking Long Term Outcomes Following Hematopoietic Cell Transplantation (HCT) for â-Thalassemia Major

Sonali Chaudhury(Northwestern University), Shalini Shenoy(Washington University in St. Louis), Colleen Rosen(Lurie Children's Hospital), Alexis A. Thompson(Children's Hospital of Philadelphia), Madeline Ma(Lurie Children's Hospital), Sandhya Kharbanda(UCSF Benioff Children's Hospital), Gregory M.T. Guilcher(University of Calgary), Mohammed Viqarrudin, Mouhab Ayas(King Faisal Specialist Hospital & Research Centre), Suhag Parikh(Emory University), Kuang‐Yueh Chiang(Emory University), Monica Bhatia(Columbia University Irving Medical Center)
Transplantation and Cellular Therapy
February 18, 2016
10.1016/j.bbmt.2015.11.312
Cited by 1

Related Papers

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial
|The Lancet|2015|518
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia
|Blood|2008|447
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients
|Transplantation and Cellular Therapy|2013|248
Unrelated Donor Cord Blood Transplantation for Children with Severe Sickle Cell Disease: Results of One Cohort from the Phase II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
|Transplantation and Cellular Therapy|2012|201